This is a guideline for the use of granulocyte-colony stimulating factor (G-CSF) in adult oncology and haematology patients
This document provides evidence-based guidance from the Northern Cancer Alliance regarding the use of Granulocyte-Colony Stimulating Factor (G-CSF) for adult patients with cancer and haematological conditions. It outlines specific criteria for prescribing G-CSF, including indications for chemotherapy support, treatment for severe neutropenic sepsis, and peripheral blood stem cell mobilisation. The guidelines cover both primary and secondary prophylaxis strategies.
G-CSF should be started not less than 24 hours and not more than 72 hours after cytotoxic treatment is completed.
Injections should continue until the neutrophil count has recovered to > 1.0 x 10 9/L on two consecutive days.
The G-CSF of choice is daily G-CSF in the form of the biosimilar Filgrastim.